Re-resection for recurrent high-grade glioma in the setting of re-irradiation: more is not always better

[1]  M Brada,et al.  High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  R. Vernhout,et al.  Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. , 2014, The Lancet. Oncology.

[3]  G. Reifenberger,et al.  EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. , 2014, The Lancet. Oncology.

[4]  B. Mann.  Overall survival benefit from surgical resection in treatment of recurrent glioblastoma. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  D. Brat,et al.  The role of radiotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline. , 2014 .

[6]  Peter Nakaji,et al.  An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity. , 2014, Journal of neurosurgery.

[7]  K. Aldape,et al.  A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[8]  E. Hattingen,et al.  Benefit of tumor resection for recurrent glioblastoma , 2014, Journal of Neuro-Oncology.

[9]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[10]  J. Olson,et al.  The role of cytoreductive surgery in the management of progressive glioblastoma , 2014, Journal of Neuro-Oncology.

[11]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. , 2013, Neuro-oncology.

[12]  J. Brøgger,et al.  γ knife surgery versus reoperation for recurrent glioblastoma multiforme. , 2012, World neurosurgery.

[13]  Mitchel S Berger,et al.  Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. , 2012, Journal of neurosurgery.

[14]  R. Stupp,et al.  New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. , 2012, European journal of cancer.

[15]  Susan M. Chang,et al.  Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? , 2011, Neuro-oncology.

[16]  G. Minniti,et al.  Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma , 2011, Journal of Neuro-Oncology.

[17]  D. Scheie,et al.  Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme , 2010, Acta neurologica Scandinavica.

[18]  P. Black,et al.  Scale to predict survival after surgery for recurrent glioblastoma multiforme. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Adam P Dicker,et al.  Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Uhm.  Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group , 2010 .

[21]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[22]  A. Brodbelt,et al.  ‘Recurrent’ glioblastoma multiforme, when should we reoperate? , 2008, British journal of neurosurgery.

[23]  J. Debus,et al.  Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  D. Frappaz,et al.  Is reoperation for recurrence of glioblastoma justified? , 2000, Oncology reports.

[25]  E. Arbit,et al.  Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel. , 2000, American journal of clinical oncology.

[26]  W. Curran,et al.  A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. , 1999, International journal of radiation oncology, biology, physics.

[27]  S. Kahraman,et al.  Radical Surgery and Reoperation in Supratentorial Malignant Glial Tumors , 1998, Minimally invasive neurosurgery : MIN.

[28]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Salcman.  Survival in glioblastoma: historical perspective. , 1980, Neurosurgery.